• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

    5.230 +0.020 (+0.38%)
    Streaming Delayed Price Updated: 12:41 PM EDT, Aug 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Arbutus Biopharma Corporation - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
    In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant... 
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
    The news is likely to come as a relief to many investors, Citi told investors in a research note. 
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
    The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines. 
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
    As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based... 
    Via Finterra
    Topics Initial Public Offering Intellectual Property Lawsuit
    Get insights into the top gainers and losers of Friday's pre-market session. ↗
    Via Chartmill
    News headline image
    Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
    Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period... 
    Via Finterra
    Topics Initial Public Offering Intellectual Property
    News headline image
    The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
    As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the... 
    Via MarketMinute
    Topics Economy Intellectual Property World Trade
    News headline image
    Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
    Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the... 
    Via PredictStreet
    Topics Initial Public Offering Intellectual Property
    News headline image
    Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum ↗
    Arbutus Biopharma (ABUS) shows strong technical health and high-growth momentum, with surging sales and earnings, positioning it for potential gains. 
    Via Chartmill
    News headline image
    Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus (ABUS) Q2 Revenue Surges 529% ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.